Innovation - IPIX STOCK NEWS

Innovation Pharmaceuticals (OTCQB:IPIX) announced a significant milestone in its Phase 2 clinical trial of Brilacidin for COVID-19, reaching 90% patient enrollment with full completion expected in about two weeks. Brilacidin, a non-peptidic defensin-mimetic, aims to treat moderate-to-severe COVID-19 in hospitalized patients, under FDA Fast Track designation. The Company highlights Brilacidin's potential as a broad-spectrum antiviral, with a current focus on inhibiting SARS-CoV-2, supported by independent studies ranking it among the top inhibitors against the virus.

Innovation Pharmaceuticals (OTCQB:IPIX) filed its SEC Form 10-Q for Q1 2021, highlighting significant advancements in the development of Brilacidin, a drug candidate targeting COVID-19. Fast Track designation was granted by the FDA, and the ongoing Phase 2 trial has seen rapid patient enrollment, reaching over 70%. Brilacidin's multi-faceted therapeutic potential has been recognized, with robust antiviral research supporting its efficacy against SARS-CoV-2. Additionally, Alfasigma plans to initiate a Phase 2 trial for Ulcerative Proctitis, with Innovation Pharmaceuticals potentially receiving significant milestone payments.

Innovation Pharmaceuticals announced that enrollment has surpassed 50% of its targeted 120 participants in a Phase 2 clinical trial of Brilacidin for moderate-to-severe COVID-19. The trial is double-blind and placebo-controlled, focusing on hospitalized patients. Brilacidin exhibits potent inhibition against various coronavirus strains and is the only non-peptidic defensin-mimetic drug candidate currently under clinical evaluation for SARS-CoV-2. The company is also pursuing FDA’s Fast Track designation for Brilacidin, aiming to address urgent antiviral needs as COVID-19 cases rise globally.

Innovation Pharmaceuticals (OTCQB:IPIX) announced that Brilacidin was featured in a presentation on COVID-19 research at George Mason University. Preliminary data indicates that Brilacidin may inhibit coronaviruses and alphaviruses. The company is currently conducting a Phase 2 clinical trial for Brilacidin in moderate-to-severe COVID-19 patients, having received FDA Fast Track designation. An independent committee has recommended increasing the treatment duration from 3 to 5 days. The global antiviral drug market is projected to reach $44 billion by 2026.

Innovation Pharmaceuticals (OTCQB:IPIX) announced that data on Brilacidin, an antiviral candidate, will be presented at the American Society of Virology’s 40th Annual Meeting in July 2021. The data shows Brilacidin's inhibitory effect on SARS-CoV-2 and various alphaviruses. Brilacidin is currently in Phase 2 clinical trials for COVID-19 treatment in hospitalized patients. Following an interim safety review, the dosing regimen has increased from 3 to 5 days to potentially enhance therapeutic outcomes. The global antiviral drug market is projected to reach $44 billion by 2026.

Innovation Pharmaceuticals (OTCQB:IPIX) announced a key update in its Phase 2 clinical trial for Brilacidin, intended for moderate-to-severe COVID-19 treatment. Following a Data Monitoring Committee's (DMC) review, the dosing regimen will extend from 3 to 5 days. Enrollment has reached 25% of the target 120 patients, with recruitment paused for interim safety evaluations. The expanded treatment duration aligns with FDA recommendations. The company aims to expedite enrollment and anticipates topline results soon, underscoring Brilacidin's potential against emerging COVID-19 variants.

Innovation Pharmaceuticals (OTCQB:IPIX) announced that a Machine Learning model ranked Brilacidin in the top 3% of compounds for effectiveness against SARS-CoV-2, as published in Bioinformatics. The study leveraged physicochemical properties to predict binding to coronavirus proteins, indicating Brilacidin's potential against COVID-19 variants. The company is encouraged by further validation and has initiated a randomized Phase 2 clinical trial for hospitalized patients. Brilacidin could address the urgent need for effective antiviral therapies amidst evolving virus strains.

Innovation Pharmaceuticals (OTCQB:IPIX) has initiated an international Phase 2 clinical trial for Brilacidin, targeting hospitalized COVID-19 patients. Currently, eight sites are involved, with 15 patients already dosed. This trial includes a randomized, double-blind, placebo-controlled design aimed at enrolling ~120 subjects. Notably, Brilacidin's extensive pre-clinical data indicates its potential to inhibit SARS-CoV-2 and various coronaviruses, positioning it as a pivotal therapeutic candidate against COVID-19. The company remains optimistic about its three-in-one therapeutic profile amidst rising global COVID-19 cases.

Innovation Pharmaceuticals (OTCQB:IPIX) announced that Brilacidin, its investigational antiviral treatment for COVID-19, displayed significant inhibition of SARS-CoV-2 in cell culture. A peer-reviewed article published in Viruses confirms Brilacidin's effectiveness against multiple strains, including those from Washington and Italy. The drug is currently in a Phase 2 trial for hospitalized COVID-19 patients, having received FDA Fast Track designation. Its mechanism suggests resistance is unlikely, differentiating it from existing treatments.